Summary of Key Points Core Viewpoint - On August 15, a total of 14 A-share listed companies disclosed their share reduction plans, with no companies announcing share increases on the same day [1]. Group 1: Companies and Their Reduction Plans - Weitang Industrial: High-tech Investment plans to reduce its shares by no more than 701,400 shares [2] - Boliview: Actual controller and concerted parties plan to reduce their holdings by no more than 3% [2] - Runbei Hangke: Shareholders Lin Xiaoke and Huang Youlian plan to reduce their holdings by no more than 0.09% [2] - Aosaikang: Shareholder Zhongyi Weiye plans to reduce its holdings by no more than 2% [2] - Jizhi Technology: Controlling shareholder's concerted parties plan to reduce their holdings by no more than 1.05% [2] - Zhaobiao Co.: Director and General Manager Wu Mingxi and CFO Lin Li plan to reduce their shares [2] - Siripu: Director and Deputy General Manager Feng Ying plans to reduce their holdings by no more than 0.4% [2] - Shutaishen: Xiangtang Group plans to reduce its holdings by no more than 2% [2] - Zhongxin Fluorine Materials: Gaobao Mining reduced 2,166,000 shares, bringing its holding ratio below 5% [2] - Aerospace Science and Technology: Zhang Shiwai plans to reduce no more than 2,600 shares [2] - Lihua Technology: Shareholder Guokexinhua plans to reduce 5.5 million shares [2] - Kang En Bei: Kang En Bei Group plans to reduce its holdings by no more than 1% [2] - Western Gold: Huiyuan Company plans to reduce its holdings by no more than 1% [2] - Changchun Yidong: Qiche Equity Company plans to reduce its holdings by no more than 2.97% [2]

Mergers and Acquisitions - ST Jinggu plans to sell 51% stake in Huayin Wood Industry, which is expected to constitute a major asset restructuring. The sale will be settled in cash and is not expected to change the controlling shareholder or actual controller. The revenue from Huayin Wood is projected to account for 87.02% of the company's total revenue in 2024, leading to a significant decline in the company's main business scale, potentially triggering delisting risk warning indicators [1] - Zhengye Technology intends to sell 92.07% stake in its subsidiary Zhengye Jiukun through public listing, with a minimum transfer price of 100,000 yuan. Post-transaction, Zhengye Jiukun and its subsidiaries will no longer be included in the company's consolidated financial statements. The transaction aims to optimize resource allocation and improve asset operation efficiency [2] - Yunnan Baiyao plans to acquire 100% stake in An Guo Shi Ju Yao Tang for 660 million yuan. Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces and has a stable profitability [3] Performance Disclosure - Chipeng Microelectronics reported a 106% year-on-year increase in net profit attributable to shareholders, reaching 90.49 million yuan, with a revenue of 636 million yuan, up 40.32% year-on-year [4] - Tongxing Technology achieved a net profit growth of 166% year-on-year, amounting to 52.48 million yuan, with a revenue of 405 million yuan, reflecting a 33.49% increase [5] - Dongfang Caifu reported a 37.27% year-on-year increase in net profit attributable to shareholders, totaling 5.567 billion yuan, with total revenue of 6.856 billion yuan, up 38.65% [6] Shareholding Changes - A shareholder, Zhongyi Weiye, plans to reduce its stake in Aosaikang by up to 2%, equivalent to 18.56 million shares, within three months after the announcement. The reduction is due to the shareholder's operational needs [7] - The controlling shareholder's concerted actor, Yiyang Investment, intends to reduce its stake in Jizhi Technology by up to 1.05%, or 273,640 shares, within three months after the announcement, driven by funding needs [8] - Feng Ying, a director and vice president of SIRUI, plans to reduce his stake by up to 0.4%, or 54,000 shares, within three months after the announcement, due to personal funding needs [9] Risk Matters - A client of Aowei New Materials, TPI Composites, has filed for bankruptcy protection, which may impact the company's performance. The company has accounts receivable of approximately 3.237 million yuan due by November 30, 2025, and is assessing the situation to protect its interests [10] - A controlling shareholder's concerted actor, Zhang Feng, has been sentenced to seven years and nine months in prison for manipulating the securities market. This judgment is final and does not affect the company's operations or profits [11]

2024年1至12月份，奥赛康的营业收入构成为：医药制造业占比97.92%，其他业务占比2.08%。 （文章来源：每日经济新闻） 奥赛康（SZ 002755，收盘价：26.35元）8月15日晚间发布公告称，北京奥赛康药业股份有限公司股东 中亿伟业控股有限公司持有公司股份约1.2亿股，占公司总股本的约12.95%。中亿伟业计划在本公告披 露之日起15个交易日后的3个月内，以集中竞价和大宗交易方式减持公司股份不超过约1856万股，不超 过公司总股本的2%。 ...

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9772 yuan, reflecting a growth of 1.81% [1]. - The fund's return over the past month is 9.64%, ranking 129 out of 328 in its category [1]. - Over the last six months, the fund has achieved a return of 47.35%, ranking 12 out of 316 [1]. - Year-to-date, the fund has a return of 45.00%, ranking 18 out of 316 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Rejig Bio: 5.63% - Kelun Pharmaceutical: 5.02% - HAO OBO: 4.36% - BeiGene: 3.61% - Yifang Bio: 3.58% - Aosaikang: 3.52% - Bid Pharma: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the fund management industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 证券代码：002755 证券简称：奥赛康 公告编号：2025-042 北京奥赛康药业股份有限公司 关于持股 5%以上股东减持计划的预披露公告 持股 5%以上的股东中亿伟业控股有限公司保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 北京奥赛康药业股份有限公司（以下简称"公司"）股东中亿伟业控股有限公 司（以下简称"中亿伟业"）持有本公司股份 120,192,033 股，占本公司总股本的 12.9495%。中亿伟业计划在本公告披露之日起 15 个交易日后的 3 个月内，以集 中竞价和大宗交易方式减持本公司股份不超过 18,563,200 股，不超过本公司总股 本的 2%。 现将有关情况公告如下： 一、股东的基本情况 1、 股东名称：中亿伟业控股有限公司 2、 截至本公告日，中亿伟业持有本公司股份 120,192,033 股，占本公司总 股本的 12.9495%，该等股份全部为无限售流通股。 二、本次减持计划的主要内容 （一）本次拟减持的具体安排 1、 减持原因：股东经营发展需要。 2、 股份来源： ...

Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9462 yuan, reflecting a growth of 2.54% [1]. - The fund's return over the past month is 11.14%, ranking 101 out of 333 in its category [1]. - Over the last six months, the fund has achieved a return of 46.50%, ranking 10 out of 327 [1]. - Year-to-date, the fund has returned 42.73%, ranking 18 out of 327 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Hotgen Biotech: 5.63% - Kelun Pharmaceutical: 5.02% - HAOYOBIO: 4.36% - BeiGene: 3.61% - Eucure Biopharma: 3.58% - Aosaikang: 3.52% - Bide Pharmaceutical: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

（文章来源：证券日报） 证券日报网讯奥赛康8月11日在互动平台回答投资者提问时表示，截至7月31日，公司的股东人数为20， 229户。 ...

Summary of the Conference Call for Aosaikang Industry and Company Overview - The conference call focuses on Aosaikang, a company in the pharmaceutical industry, particularly in the fields of generic drugs and innovative drugs [2][3][4]. Key Points and Arguments Generic Drug Business - Aosaikang's generic drug business has shown signs of recovery following the PPI collection, with new generics like Rabeprazole and key products like Delafloxacin set to launch, contributing to cash flow [2][3]. - The chemical drug collection rules are becoming more predictable and moderate, leading to stable profit releases from the generic drug business [2][3]. Innovative Drug Development - Aosaikang's first innovative drug, Ligatinib (for EGFR mutation non-small cell lung cancer), is expected to launch in 2025, with a significant market potential but facing intense competition [2][3][5]. - The Claudin 18.2 monoclonal antibody is anticipated to be the first domestically produced drug in China, particularly promising in the gastric cancer field [2][3][5]. - Other innovative drugs, such as Mavacitamab and dual antibodies for ophthalmology, are progressing steadily, with plans to submit one application and launch one product each year [2][3][5]. Smart Platform Technology - The Smart platform utilizes masking peptide technology to control the release of active ingredients, addressing issues related to short half-lives and high toxicity of traditional cytokine therapies [2][4][6]. - This technology is applicable across various treatment modalities, including antibodies and ADCs, and has shown potential in multiple therapeutic areas [4][6]. Market Competition and Challenges - The domestic EGFR TKI market is highly competitive, with eight third-generation EGFR TKIs already available. Aosaikang faces competition from companies like Innovent Biologics, which has strong commercialization capabilities [3][13]. - The Claudin 18.2 market is also competitive, with existing products showing varying efficacy, but Aosaikang's combination therapies are expected to perform better [12]. Additional Important Insights - The engineering modifications in cytokine therapies aim to enhance efficacy by designing dual-function molecules and utilizing prodrug technologies to improve targeting and reduce side effects [9][10]. - Aosaikang's innovative platform is expected to significantly enhance immune therapy outcomes, with promising clinical data anticipated for products like SKG315 and SKG915 by the second half of 2025 [11]. - The overall outlook for Aosaikang is optimistic, with a recovery in the generic drug sector and a robust pipeline of innovative products supported by advanced technology platforms [14].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **China A-shares market** and its performance in July 2025, highlighting solid price gains across various sectors [1][2]. Core Insights and Arguments - **Sector Performance**: - **Healthcare**: Led with a **13.5%** increase in July and **23.1%** year-to-date (YTD) performance, driven by recovering demand and strong drug pipelines [2][8]. - **IT**: Increased by **6.7%** in July and **14.7%** YTD, benefiting from Nvidia's resumption of sales to China [2][8]. - **Materials**: Gained **6.4%** in July and **18.0%** YTD, supported by government initiatives against overcapacity [2][9]. - **Energy**: Saw a **4.7%** increase in July but a decline of **1.8%** YTD [2]. - **Real Estate**: Increased by **4.5%** in July but declined **2.3%** YTD [2]. - **Financials**: Only **2.1%** increase in July and **10.5%** YTD, with some companies experiencing significant declines [2][10]. - **Market Drivers**: - The **CSI300** index rose **3.5%** in July, with improving liquidity and solid GDP growth of **5.2%** year-on-year (y-y) in Q2 2025 [5][39]. - **Net inflows** into A-shares totaled **US$193 million**, primarily in Financials, IT, and Materials, while Industrials and Consumer Discretionary saw outflows [5][14]. - **Macroeconomic Indicators**: - **GDP Growth**: China's GDP growth was **5.2%** y-y, with nominal GDP growth at **3.9%** y-y, indicating a decline in the GDP deflator to **-1.2%** [5][39]. - **Industrial Production**: Increased by **6.8%** y-y, with notable growth in high-tech sectors [5][42]. - **Retail Sales**: Grew by **4.8%** y-y, below expectations, indicating weak consumer sentiment [5][39]. - **Trade**: Exports rose **5.8%** y-y, with a rebound in exports to the US [5][41]. Additional Important Insights - **Margin Financing**: The margin buying as a percentage of A-share turnover rose to **10.5%** at the end of July from **9.6%** at the end of June, indicating increased investor confidence [5][24]. - **Fund Issuance**: Equity mutual fund issuance remained stable at **Rmb18 billion** in July, compared to **Rmb21 billion** in June [5][27]. - **Shareholding Structure**: By the end of 2024, retail investors held **42%**, controlling shareholders **43%**, domestic financial institutions **12%**, and foreign investors **3%** of A-shares' total market cap [5][28]. This summary encapsulates the key points from the conference call, providing a comprehensive overview of the current state of the China A-shares market and its underlying economic factors.

Group 1 - The stock price of Aosaikang as of August 4, 2025, is 28.29 yuan, down 0.11 yuan or 0.39% from the previous trading day [1] - The stock experienced significant volatility during the day, with a high of 28.67 yuan and a low of 26.31 yuan, resulting in an amplitude of 8.31% [1] - The trading volume for the day was 238,902 hands, with a total transaction amount of 650 million yuan [1] Group 2 - Aosaikang's main business is in the chemical pharmaceutical sector, focusing on the research and production of innovative drugs [1] - The company's product pipeline covers multiple therapeutic areas, including the digestive system and anti-infection, with particular market attention on the development of drugs related to Helicobacter pylori [1] - As a representative pharmaceutical enterprise in Beijing, Aosaikang has accumulated technical expertise in its niche [1] Group 3 - In the early trading session on August 4, Aosaikang saw a rapid rebound, with a rise of over 2% within five minutes, increasing from 26.83 yuan to 27 yuan, with a transaction amount of 239 million yuan during that period [1] - The net inflow of main funds for the day was 62.44 million yuan, with a cumulative net inflow of 131 million yuan over the past five trading days [1]